about
Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A.A novel AMPK-dependent FoxO3A-SIRT3 intramitochondrial complex sensing glucose levels.Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy.In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).The longevity SNP rs2802292 uncovered: HSF1 activates stress-dependent expression of FOXO3 through an intronic enhancer.
P50
Q27853215-7CD328AD-FEC7-439F-8274-867375DABB09Q34008781-7A973FA7-049B-416F-AC4D-3B1F9BEF5284Q37183416-40ED326C-D1EA-4D65-87E0-0FB646186D2BQ39064624-110E0756-6A0F-4A10-B019-8D79042C88C6Q42827279-25A52CA9-B96D-45FE-B5F6-1F1963A0CB6DQ50315356-E8793CC1-D3BF-4A48-8F29-1D6BB25FFEFDQ52726054-F1610608-7D79-45C1-A10D-6A5DDE1A51CAQ53686929-3BCCE07B-5FD4-4B6A-8A42-4B8659AF804E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alessia Peserico
@ast
Alessia Peserico
@en
Alessia Peserico
@es
Alessia Peserico
@nl
type
label
Alessia Peserico
@ast
Alessia Peserico
@en
Alessia Peserico
@es
Alessia Peserico
@nl
prefLabel
Alessia Peserico
@ast
Alessia Peserico
@en
Alessia Peserico
@es
Alessia Peserico
@nl
P106
P1153
57190109353
P31
P496
0000-0003-2025-2419